Skip to main
COYA
COYA logo

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics Inc. is demonstrating a positive outlook due to its strengthened cash position, which has been bolstered through private placements and strategic investments aimed at achieving key clinical milestones by 2025. The company's increased investment in research and development, with expenses reaching $11.9 million, underscores its commitment to advancing its innovative multi-modality Treg therapies targeted at neurodegenerative, autoimmune, and metabolic diseases. Additionally, the partnership with Reddy's showcases confidence in Coya's differentiated approach to treatment, particularly for ALS, which could significantly enhance the company's potential impact in addressing unmet medical needs in this space.

Bears say

Coya Therapeutics operates in a highly challenging landscape for amyotrophic lateral sclerosis (ALS) drug development, which is characterized by a history of high-profile failures due to the disease's complexity and ineffective clinical trial designs. Despite Coya’s unique multi-modality approach to therapy, concerns remain regarding the robustness of their efficacy in the face of the broader patient population, especially given prior unsuccessful single-mechanism treatments. The company's reliance on a novel strategy to enhance regulatory T cell function may not be sufficient to overcome the entrenched difficulties presented by neuroinflammation and motor neuron degeneration in ALS.

COYA has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 7 analysts, COYA has a Strong Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.